REGENXBIO announces new positive data from AFFINITY DUCHENNE trial of RGX-202. Learn more: ir.regenxbio.com/news-releases/…

REGENXBIO reports second quarter 2024 financial results and recent operational highlights. Learn more: ir.regenxbio.com/news-releases/…

REGENXBIO will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Learn more: ir.regenxbio.com/news-releases/…

Thank you to Foundation for FDA for bringing together stakeholders, including regulators, patient advocates and industry, to discuss the important role of biomarkers in developing new therapies for rare disease. Read the report about the unmet need for patients with neuronopathic MPS.

Our team was pleased to participate in CureDuchenne's family workshop in Minneapolis this past weekend. Heartfelt thanks to CureDuchenne for their commitment to supporting and educating the Duchenne community.

At REGENXBIO, two of our core values are innovation and perseverance – both incredibly important in advancing the science of gene therapy. Hear from Ayda Mayer, Executive Director, Vector Core, as she reflects on how our approach to science and innovation makes REGENXBIO unique.

Today is #WomensEqualityDay, which commemorates the passage of the 19th Amendment, granting women the right to vote in the United States. We are proud that women represent more than half of our team, leading advancements in the lab, in the clinic and across REGENXBIO.

Today, we announced that we will be sharing data from our RGX-121 program for the treatment of MPS II, also known as Hunter syndrome, at the SSIEM 2024 Annual Symposium. Learn more: ir.regenxbio.com/news-releases/… #SSIEM2024

At REGENXBIO, innovation isn’t just a buzzword; it’s one of our core values and is woven into the fabric of our culture and work. Hear from Ye Liu, VP of Gene Therapy Research on why he thinks REGENXBIO is transforming gene therapy research.

REGENXBIO will participate in upcoming investor conferences. Learn more: ir.regenxbio.com/news-releases/…

Happy Labor Day from REGENXBIO! Today we honor and celebrate the hard work and perseverance of our amazing team. Your dedication drives our mission to accelerate and advance the development of AAV Therapeutics that have the potential to make a profound impact for patients.

New data announced today continues to support RGX-121 as the first potential first gene therapy and one-time treatment for MPS II and the first treatment in the U.S. that addresses the neurocognitive decline associated with this disease. Learn more: ir.regenxbio.com/news-releases/… #SSIEM

September is #NewbornScreeningAwarenessMonth, which raises public awareness of the importance of newborn screenings in supporting early detection of genetic diseases and enabling potentially life-changing early interventions. Learn more: everylifefoundation.org/newborn-screen…

As we approach #WorldDuchenneAwarenessDay, meet Dr. Naz Dastgir, a neuromuscular neurologist and the clinical development lead for our RGX-202 program for Duchenne.

Today on #WorldDuchenneAwarenessDay, we join the Duchenne community to spread awareness of this rare degenerative muscle disease. This year’s theme #RaiseYourVoiceforDuchenne highlights the importance of amplifying the voices of those living with Duchenne. worldduchenneday.org/today-is-world…

Yesterday we welcomed Katie Morgan and her son Andy, who lives with Duchenne, to REGENXBIO. Andy’s energy and enthusiasm brought smiles to everyone’s faces. We ended the day with a walk to support Parent Project Muscular Dystrophy (PPMD). Thank you, Katie and Andy, for spending the day with us!

We’re proud of our culture and the ways our people come together to help patients. The teams that are part of our REGENXBIO Manufacturing Innovation Center exemplify collaboration in action. Hear from Katie Masterson about how our manufacturing capabilities set us apart.

Yesterday was the start of #HispanicHeritageMonth, a month-long celebration of Hispanic and Latino history and culture. Join us this month as we honor the contributions of some of our Hispanic and Latino team members. Learn more here: latino.si.edu/learn/teaching…

As we advance our pipeline of next-generation gene therapies towards commercialization, we are excited to welcome Mitchell Chan as EVP and Chief Financial Officer, succeeding Vit Vasista. Learn more about today's announcement: ir.regenxbio.com/news-releases/… $RGNX

At REGENXBIO, we often talk about how “what we do matters” - to patients, to their families, and to their communities. Hear from Selase Enuameh, Sr. Scientist, Cell Line Development, as he reflects on what this means to him.